Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

8 Aug 2018

Abstract excerpt

With the availability of immunomodulatory imide drugs (IMiDs) and proteasome inhibitors (PI), most patients with immunoglobulin light chain amyloidosis (AL) receive induction therapy before autologous hematopoietic stem cell transplantation (auto-HCT). In this study we evaluated the type of induction therapy and its impact on the outcome of auto-HCT in AL. We identified 128 patients with AL who underwent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Chronic Myeloid Leukemia Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30016656
DOI: 10.1016/j.bbmt.2018.07.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell TransplantationPMID 30016656Read ↗

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationSemantic proximity Read ↗

Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric PatientsSemantic proximity Read ↗

Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantationSemantic proximity Read ↗

Divergent Clinical Phenotypes, Organ Involvement, and Survival in AL Amyloidosis and Light Chain Deposition Disease: Insights From a Large Single-Center CohortSemantic proximity Read ↗

Autoimmune Complications after Hematopoietic Stem Cell Transplantation in Children with Nonmalignant DisordersSemantic proximity Read ↗

Epidemiology of Systemic Light-Chain (AL) AmyloidosisSemantic proximity Read ↗

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficienciesSemantic proximity Read ↗

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk B-cell Lymphoma Patients: Final Long-term Analysis From a Prospective Multicenter Phase-ii TrialSemantic proximity Read ↗

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.Semantic proximity Read ↗

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationSemantic proximity Read ↗

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.Semantic proximity Read ↗

Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.